Cover Image
Market Research Report

Market Spotlight: Idiopathic Pulmonary Fibrosis (IPF)

Published by Datamonitor Healthcare Product code 914878
Published Content info 54 Pages
Delivery time: 1-2 business days
Price
Back to Top
Market Spotlight: Idiopathic Pulmonary Fibrosis (IPF)
Published: September 24, 2019 Content info: 54 Pages
Description

This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • Datamonitor Healthcare estimates that in 2018, there were 305,450 incident and 940,840 prevalent cases of idiopathic pulmonary fibrosis (IPF) in adults aged 20 years and older worldwide, and forecasts those numbers to increase to 342,000 incident cases and 1.1 million prevalent cases by
  • 2027. Roche's Esbriet and Boehringer Ingelheim's Ofev are the only approved drugs for IPF. These drugs are administered via the oral route.
  • Industry-sponsored drugs in active clinical development for IPF are spread evenly across Phase I and Phase II, with two drugs in Phase III.
  • Therapies in development for IPF focus on a wide variety of targets. The majority of pipeline drugs in development are administered via an oral formulation.
  • The only high-impact upcoming event in the IPF space is topline Phase IIa trial results for PLN-74809. The overall likelihood of approval of a Phase I respiratory-other asset is 9%, and the average probability a drug advances from Phase III is 53.8%. Drugs, on average, take 11.3 years from Phase I to approval, compared to 9.5 years in the overall respiratory space.
  • There have been 22 licensing and asset acquisition deals involving IPF drugs during 2014-19. The $4,275m global research and development collaboration agreement signed in 2019 between Gilead and Galapagos, pursuant to which Gilead gained access to Galapagos's drug discovery platform and current and future pipeline outside of Europe, was the largest deal.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for IPF have been in the early and midphases of development, with 64% of trials in Phase I-II, and 36% in Phase III-IV.
  • The US has a substantial lead in the number of IPF clinical trials globally. The UK leads the major EU markets, while Israel has the top spot in Asia.
  • Clinical trial activity in the IPF space is dominated by completed trials. Boehringer Ingelheim has the highest number of completed clinical trials for IPF, with 15 trials.
  • Boehringer Ingelheim leads industry sponsors with the highest overall number of clinical trials for IPF, followed by Roche.
Table of Contents
Product Code: DMKC0205920

TABLE OF CONTENTS

CONTENTS

6 OVERVIEW

7 KEY TAKEAWAYS

8 DISEASE BACKGROUND

8 Disease definition

8 Patient segmentation

8 Symptoms

8 Risk factors

9 Diagnosis

10 TREATMENT

10 Pharmacologic treatment

10 Non-pharmacologic treatments

12 EPIDEMIOLOGY

17 MARKETED DRUGS

19 PIPELINE DRUGS

26 RECENT EVENTS AND ANALYST OPINION

26 GLPG1690 for IPF (July 14, 2019)

27 BG00011 for IPF (May 23, 2018)

28 KD025 for IPF (May 22, 2018)

30 Pamrevlumab for IPF (May 21, 2018)

31 GLPG1690 for IPF (May 20, 2018)

33 PBI-4050 for IPF (May 20, 2018)

35 PRM-151 for IPF (May 20, 2018)

38 KEY UPCOMING EVENTS

39 KEY REGULATORY EVENTS

39 BTD Makes Promedior's PRM-151 Stand Out In IPF Race; Will Bristol Bite?

40 PROBABILITY OF SUCCESS

41 LICENSING AND ASSET ACQUISITION DEALS

41 Boehringer Further Buoys IPF Portfolio With Bridge's Autotaxin Inhibitor

41 $5bn Galapagos Deal Won't Be Last For Gilead, Says O'Day

42 Galapagos Licenses Global Rights To Fibrocor's IPF Program

42 TiumBio Inks $74m License With Chiesi For Potential IPF Drug

42 Deals Shaping The Medical Industry, October 2018

42 United Therapeutics Licenses Rights To Samumed's IPF Candidate

44 PARENT PATENTS

45 REVENUE OPPORTUNITY

46 CLINICAL TRIAL LANDSCAPE

47 Sponsors by status

48 Sponsors by phase

49 Recent events

51 BIBLIOGRAPHY

52 Prescription information

53 APPENDIX

LIST OF FIGURES

  • 14 Figure 1: Trends in incident cases of IPF, 2018-27
  • 16 Figure 2: Trends in prevalent cases of IPF, 2018-27
  • 19 Figure 3: Overview of pipeline drugs for IPF in the US
  • 19 Figure 4: Pipeline drugs for IPF, by company
  • 20 Figure 5: Pipeline drugs for IPF, by drug type
  • 20 Figure 6: Pipeline drugs for IPF, by classification
  • 30 Figure 7: KD025 for IPF (May 22, 2018): Phase II - 207
  • 31 Figure 8: Pamrevlumab for IPF (May 21, 2018): Phase II - PRAISE
  • 33 Figure 9: GLPG1690 for IPF (May 20, 2018): Phase IIa - FLORA
  • 35 Figure 10: PBI-4050 for IPF (May 20, 2018): Phase II - Canada
  • 37 Figure 11: PRM-151 for IPF (May 20, 2018): Phase II - PRM-151-202
  • 38 Figure 12: Key upcoming events in IPF
  • 40 Figure 13: Probability of success in the IPF pipeline
  • 41 Figure 14: Licensing and asset acquisition deals in IPF, 2014-19
  • 44 Figure 15: Parent patents in IPF
  • 46 Figure 16: Clinical trials in IPF
  • 46 Figure 17: Top 10 drugs for clinical trials in IPF
  • 47 Figure 18: Top 10 companies for clinical trials in IPF
  • 47 Figure 19: Trial locations in IPF
  • 48 Figure 20: IPF trials status
  • 49 Figure 21: IPF trials sponsors, by phase

LIST OF TABLES

  • 13 Table 1: Incident cases of IPF, 2018-27
  • 15 Table 2: Prevalent cases of IPF, 2018-27
  • 18 Table 3: Marketed drugs for IPF
  • 21 Table 4: Pipeline drugs for IPF in the US
  • 26 Table 5: GLPG1690 for IPF (July 14, 2019)
  • 27 Table 6: BG00011 for IPF (May 23, 2018)
  • 28 Table 7: KD025 for IPF (May 22, 2018)
  • 30 Table 8: Pamrevlumab for IPF (May 21, 2018)
  • 32 Table 9: GLPG1690 for IPF (May 20, 2018)
  • 34 Table 10: PBI-4050 for IPF (May 20, 2018)
  • 35 Table 11: PRM-151 for IPF (May 20, 2018)
  • 45 Table 12: Historical global sales, by drug ($m), 2014-18
  • 45 Table 13: Forecasted global sales, by drug ($m), 2019-23
Back to Top